GSK's Top Selling Vaccine Can Potentially Reduce Dementia Risk, Research Suggests
GSK's Top Selling Vaccine Can Potentially Reduce Dementia Risk, Research Suggests
Scientists have discovered that the shingles vaccine Shingrix, developed by GSK Plc (NYSE:GSK), may reduce the risk of dementia, a finding that could significantly impact public health.
科学家们发现，由GlaxoSmithKline（纽交所：GSK）开发的带状疱疹疫苗Shingrix可能会降低痴呆风险，这一发现可能会对公共健康产生重大影响。
The research, published in Nature Medicine, showed that individuals vaccinated with Shingrix lived an average of 164 days longer without a dementia diagnosis compared to those who received the older Zostavax vaccine.
《自然医学》发表的研究表明，接种Shingrix疫苗的个体被诊断为痴呆的时间比接种老版本的Zostavax疫苗的个体多长164天。
Related: GSK Says Its Blockbuster Shingles Vaccine Shows High Efficacy Even After 10 Years
相关：GSK表示其畅销带状疱疹疫苗在10年后仍表现出高效性
The study, led by Maxime Taquet, a clinical lecturer in Oxford University's psychiatry department, analyzed data from 200,000 people.
牛津大学精神病学系的临床讲师Maxime Taquet带领的研究分析了20万人的数据。
Taquet stated the findings were "convincing" and called for further research to validate the hypothesis that shingles vaccination might prevent dementia.
Taquet称发现令人信服，并呼吁进一步研究验证带状疱疹疫苗可能预防痴呆症的假设。
Shingles is an infection caused by a virus. The main symptom is a painful rash. The virus that causes shingles is called varicella zoster.
带状疱疹是由病毒引起的感染。主要症状是疼痛性皮疹。引起带状疱疹的病毒称为水痘-带状疱疹病毒。
Shingles, or herpes zoster, occurs when the dormant varicella-zoster virus, which causes childhood chickenpox, reactivates.
带状疱疹或称为Herpes zoster，是指引起儿童水痘的休眠水痘-带状疱疹病毒重新激活的疾病。
The switch from Zostavax to Shingrix in the U.S. health systems in 2017 allowed researchers to compare dementia rates among over 100,000 individuals vaccinated with either vaccine.
2017年在美国健康系统中从Zostavax转换到Shingrix疫苗，使研究人员能够比较接种其中一种疫苗的超过100,000人的痴呆率。
Shingrix showed a 17% lower risk of dementia than Zostavax and a 23-27% lower risk than vaccines for other infections, such as flu and tetanus.
Shingrix疫苗的痴呆风险比Zostavax低17％，比其他感染（如流感和破伤风）的疫苗风险低23-27％。
Citing Sheona Scales, director of research at the Alzheimer's Research U.K. charity, the Financial Times report stressed the importance of further research to understand the biological mechanisms behind Shingrix's potential protective effect against dementia.
引用阿尔茨海默病研究英国慈善机构的研究主管Sheona Scales的话，金融时报报道强调了进一步研究理解Shingrix潜在保护作用背后的生物机制的重要性。
While the study adds to the evidence linking shingles vaccination with reduced dementia risk, Scales also pointed out other established dementia risk factors.
尽管该研究增加了接种带状疱疹疫苗与降低痴呆风险之间的证据，但Scales指出了其他已知的痴呆风险因素。
Shingrix has become one of GSK's top-selling products, generating 3.4 billion pounds in revenue worldwide in 2023, with Q4 2023 representing the highest-ever quarter of sales.
Shingrix已成为GSK最畅销的产品之一，在2023年全球实现34亿英镑的营业收入，Q4 2023年实现了有史以来最高的季度销售额。
GSK acknowledged the new study as part of the "growing body of evidence" suggesting a connection between shingles vaccination and reduced dementia risk.
GSK将这项新研究视为表明带状疱疹疫苗与降低痴呆风险之间存在联系的“越来越多的证据”之一。
The company plans to present additional data on Shingrix at an upcoming Alzheimer's conference in Philadelphia.
该公司计划在即将于费城举行的阿尔茨海默病会议上展示有关Shingrix的补充数据。
Price Action: GSK stock is up 2.50% at $40.04 at the last check on Friday.
股价表现：上周五最后一次查询时，GSK股价上涨2.50％，报40.04美元。
- Bristol Myers Squibb Witnesses Strong Demand For 'Newer Drugs' As Q2 Earnings Beat Expectations, Raises 2024 Profit Forecast.
- Bristol Myers Squibb区分“新药”需求旺盛，2022年第二季度盈利超过预期，将2024年盈利预期上调。
Photo via Wikimedia Commons
照片通过Wikimedia Commons